TITLE

Aldosterone Antagonism Fails to Attenuate Age-Associated Left Ventricular Fibrosis

AUTHOR(S)
Hyun Seok Hwang; Cirrincione, Georgina; Thomas, D. Paul; McCormick, Richard J.; Boluyt, Marvin O.
PUB. DATE
April 2007
SOURCE
Journals of Gerontology Series A: Biological Sciences & Medical ;Apr2007, Vol. 62 Issue 4, p382
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Collagen accumulates disproportionately in cardiac remodeling induced by hypertension and associated with advancing age. Spironolactone (Spiro), an aldosterone antagonist, attenuates the accumulation of collagen induced by hypertension. It was hypothesized that Spiro would attenuate the age-associated increase in percent collagen in the heart. Female Fisher 344 rats at 3 months (Y), 12 months (M), and 21 months (O) of age were treated with Spiro (30 mg/kg/d) or vehicle (Veh) for 2 months, yielding six groups: Y-Veh, Y-Spiro, M-Veh, M-Spiro, O-Veh, and O-Spiro. Hearts were harvested for immunoblotting, RNA blotting, and biochemical analysis. Percent collagen in the left ventricle and septum was greatest in the oldest rats. Spiro did not significantly attenuate the age-associated increase in collagen fraction or the age-associated increases in expression of atrial natriuretic factor and β-myosin heavy chain messenger RNA. Chronic aldosterone antagonism does not attenuate the age-associated increase in collagen fraction in the female Fisher 344 rat heart.
ACCESSION #
25540172

 

Related Articles

  • Aldosterone Receptor Antagonists for Hypertension: What Do They Offer? Liew, Danny; Krum, Henry // Drugs;2003, Vol. 63 Issue 19, p1963 

    Aldosterone is an important and independent target for therapeutic intervention in hypertension and hypertension-related diseases. Its actions, once thought to be limited to the distal convoluted tubule of the kidney, are now recognised to be wide-ranging, including interactions with...

  • The Risks and Benefits of Therapy with Aldosterone Receptor Antagonist Therapy. Sica, Domenic A. // Current Drug Safety;Jan2007, Vol. 2 Issue 1, p71 

    Spironolacotone and eplerenone are mineralocorticoid-blocking agents. These compounds block both the epithelial and non-epithelial actions of aldosterone with the latter assuming increasing clinical importance. Spironolactone and eplerenone both effectively reduce blood pressure either as mono-...

  • Inspra.  // Formulary;Nov2002, Vol. 37 Issue 11, p553 

    Focuses on Pharmacia & Upjohn Inc.'s aldosterone blocker Inspra, generic name eplerenone. Use of Inspra for treating hypertension; Effectiveness and safety of the drug; Recommended dosage.

  • Fresh from the pipeline: Eplerenone. Brown, Ruth; Quirk, Jeremy; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Mar2003, Vol. 2 Issue 3, p177 

    In September 2002, eplerenone (Inspra; Pharmacia), the first selective aldosterone receptor antagonist, was approved by the FDA for the treatment of hypertension. Will it become as successful as established blockbuster drugs that also target the rennin-angiotensin-aldosterone system?

  • EXPERIENCE WITH THE USE OF AN ALDOSTERONE ANTAGONIST IN SELECTED HYPERTENSIVE PATIENTS. Kert, Morley J.; Tarr, Lester W.; Frank, Stanley; Gold, Ernest; Okun, Ronald; Maxwell, Morton // Angiology;Nov1972, Vol. 23 Issue 10, p617 

    Eleven patients selected from a hypertension clinic were given spironolactone (300 mg/day) for four weeks. Six of the patients had spontaneous hypokalemia prior to the spironolactone therapy and five were control patients. Spironolactone caused significant reduction in blood pressure...

  • Aldosterone Blockade Reduces Mortality without Changing Cardiac Remodeling in Spontaneously Hypertensive Rats. Cezar, Marcelo D.M.; Damatto, Ricardo L.; Martinez, Paula F.; Lima, aline R.R.; Campos, Dijon H.S.; Rosa, Camila M.; Guizoni, Daniele M.; Bonomo, Camila; Cicogna, antonio C.; Gimenes, Rodrigo; Pagan, Luana U.; Okoshi, Marina P.; Okoshi, Katashi // Cellular Physiology & Biochemistry (Karger AG);Dec2013, Vol. 32 Issue 5, p1275 

    Background: The role of aldosterone blockers during transition from long-term compensated hypertrophy to dilated failure is not completely understood. In this study we evaluated the effects of early administration of spironolactone on cardiac remodeling, myocardial function, and mortality in...

  • Early Spironolactone Treatment Attenuates Heart Failure Development by Improving Myocardial Function and Reducing Fibrosis in Spontaneously Hypertensive Rats. Cezar, Marcelo D.M.; Damatto, Ricardo L.; Pagan, Luana U.; Lima, aline R.R.; Martinez, Paula F.; Bonomo, Camila; Rosa, Camila M.; Campos, Dijon H.S.; Cicogna, antonio C.; Gomes, Mariana J.; Oliveira-Jr, Silvio a.; Blotta, Daniella a.; Okoshi, Marina P.; Okoshi, Katashi // Cellular Physiology & Biochemistry (Karger AG);Jul2015, Vol. 36 Issue 4, p1453 

    Background: We evaluated the role of the aldosterone blocker spironolactone in attenuating long-term pressure overload-induced cardiac remodeling and heart failure (HF) in spontaneously hypertensive rats (SHR). Methods and Results: Thirteen month-old male SHR were assigned to control (SHR-C,...

  • Antihypertensive and Cardiorenal Protective Effects of SM-368229, a Novel Mineralocorticoid Receptor Antagonist, in Aldosterone/Salt-Treated Rats. Nariai, Tetsuro; Fujita, Katsuya; Mori, Masaya; Katayama, Seiji; Hori, Seiji; Matsui, Kazuki // Pharmacology;2012, Vol. 89 Issue 1/2, p44 

    The purpose of this study was to evaluate the effects of SM-368229, a novel mineralocorticoid receptor (MR) antagonist, on the blood pressure and cardiorenal injury markers in aldosterone/salt-treated hypertensive rats, in comparison to those of spironolactone (SPI). Uninephrectomized rats,...

  • ACP Journal Club. In resistant hypertension, add-on spironolactone reduced SBP more than placebo, doxazosin, or bisoprolol over 12 wk. Rosenberg, Mark; Stephens, Elizabeth // Annals of Internal Medicine;2/16/2016, Vol. 164 Issue 4, pJC16 

    A review of the article "Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, doubleblind, crossover trial," by B. Williams and colleagues, which appeared in the periodical "Lancet" in 2015, is...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics